Anti-Inflammatory Drugs Market Size to Exceed USD 210.02 Bn by 2032

The Anti-Inflammatory Drugs Market, estimated at USD 115.55 Bn in 2025, is expected to exhibit a CAGR of 8.9% and reach USD 210.02 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics:

Global anti-inflammatory drugs market growth is driven by rising prevalence of inflammatory diseases and increasing research & development investments. Growing geriatric population worldwide can increase inflammatory conditions that are highly prevalent among the elderly people. According to estimates, over 350 million people suffer from arthritis globally. Favorable government initiatives to create awareness about arthritis diagnoses and treatments can boost adoption of anti-inflammatory drugs. However, expiry of patents of blockbuster drugs and side effects associated with long-term usage of anti-inflammatory medications can hamper the market growth.

Increasing prevalence of arthritis and other inflammatory diseases

Global anti-inflammatory drugs market growth is driven by rising prevalence of arthritis and other inflammatory diseases across the world. Arthritis is one of the most common causes of disability globally. According to the Arthritis Foundation, over 54 million U.S. adults suffer from arthritis. The prevalence of arthritis is projected to increase dramatically due to aging populations and rising obesity rates. This growing disease burden boosts demand for anti-inflammatory medications for relieving pain and managing symptoms.

Growing healthcare expenditure in emerging economies

Rising healthcare expenditure in emerging economies like India, China, Brazil, and others can drive the market growth. These countries are witnessing strong economic growth that increases disposable incomes and allow people to spend more on managing existing health conditions and treatments. Governments also work towards expanding health insurance coverage through various schemes that improves access to anti-inflammatory drugs. Growing middle-class population in developing regions present a huge potential customer base and market players are actively focusing on these markets for future business growth.

Patent expiries of blockbuster drugs

Patent expiry of several blockbuster drugs over recent years can hamper the market growth. When drugs lose their patent protection, cheaper generic versions enter the market which gradually erode the sales and market share of original brand name drugs. For instance, the patent expiration of Merck's Cox-2 inhibitor drug Vioxx in 2012 allowed entry of generics from numerous companies. Similarly, expired patents on popular drugs like Celebrex and Mobic resulted in declining brand revenues as more patients opted for cheaper generics.

Pricing pressures and reimbursement policies

Stringent drug pricing control regulations and reimbursement policies imposed by governments worldwide can pose challenge for the anti-inflammatory drugs market growth. Due to rising healthcare costs, countries are focusing on lowering drug prices to improve accessibility. However, lower prices affect profit margins for pharmaceutical companies. Moreover, policies restricting the use of expensive branded drugs in place of cheaper generics also limit inclusion of new drugs developed by companies in formularies and drug lists.

Innovation in biosimilars and monoclonal antibodies

With expiry of patents on blockbuster drugs, there is huge potential for development of biosimilar versions. Biosimilars are biologic products that are similar to an original product but not exact replicas. These offer cost savings as compared to originator biologics while maintaining comparable safety and efficacy. Many leading players have established capabilities in biosimilars and their launch of biosimilars for anti-TNF agents and other major biologics can offer new opportunities.

Focus on emerging indications

Traditionally, the major indications targeted by anti-inflammatory drugs were rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. However, ongoing research has established roles of inflammation in various other diseases like psoriasis, inflammatory bowel disease, asthma, and others. Drugs approved or in pipeline for new diseases expand the scope of conditions that can be potentially treated. This significantly enlarges the potential patient population benefiting from anti-inflammatory therapies.

Link - https://www.coherentmarketinsights.com/market-insight/anti-inflammatory-drugs-market-4327

Key Development

• In April 2024, Glenmark Pharmaceuticals, a pharmaceutical company, announced that it had received FDA approval to sell a generic version of the anti-inflammatory drug Acetaminophen and Ibuprofen tablets (250 mg/125 mg) in the U.S. This product is the generic equivalent of Haleon US Holdings, LLC's Advil 2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC).
• In March 2024, Endo International plc, a pharmaceutical company, launched ibuprofen-famotidine 800 mg/26.6 mg tablets through its subsidiary- Par Pharmaceutical, Inc. This generic version of Amgen's DUEXIS aims to offer healthcare providers and patients more affordable treatment options for relieving the signs and symptoms of rheumatoid arthritis and osteoarthritis.
• In February 2024, Hikma Pharmaceuticals PLC launched COMBOGESIC IV in the U.S., an intravenous medication combining acetaminophen (1,000 mg) and ibuprofen (300 mg). Approved by the U.S. FDA in October 2023, it provides opioid-free pain relief for adults. This formulation is intended for situations requiring intravenous administration, such as mild to moderate pain relief and management of moderate to severe pain, often used adjunctively with opioid analgesics as clinically necessary.
• On May 18, 2023, AbbVie, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved RINVOQ (upadacitinib) for treating adults with moderately to severely active Crohn's disease who have shown inadequate response or intolerance to one or more TNF blockers
• On March 11, 2022, Pfizer, Inc. announced the successful acquisition of Arena Pharmaceuticals, a clinical-stage company focused on developing novel therapies for various immuno-inflammatory diseases

Key Players: Pfizer, Inc., Johnson & Johnson, Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Eli Lilly and Company, Sanofi, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Roche Holding AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Horizon Therapeutics plc